

Supplemental Table 6. Percentage Change From Baseline in Soluble Biomarkers

Biomarker, mean (95% CI), <i>P</i> value*	Placebo n=65	Lutikizumab n=63
Serum C3M, ng/mL		
Week 4	1.3 (−2.6, 5.3), 1.00	−6.2 (−10.0, −2.3), <0.01
Week 16	0.9 (−3.0, 5.0), 1.00	−2.2 (−6.3, 2.1), 0.93
Week 26	−0.5 (−4.4, 3.6), 1.00	−5.4 (−9.4, −1.3), 0.04
Serum CRPM, ng/mL		
Week 4	−1.1 (−4.6, 2.5), 1.00	−4.5 (−8.0, −0.8), 0.056
Week 16	1.9 (−1.7, 5.6), 0.92	−3.3 (−7.0, 0.6), 0.29
Week 26	2.7 (−1.1, 6.6), 0.49	−3.3 (−7.1, 0.6), 0.30
Serum HA, ng/mL		
Week 4	−4.5 (−14.1, 6.2), 1.00	18.1 (5.7, 32.0), 0.01
Week 16	8.2 (−2.8, 20.5), 0.45	4.6 (−7.2, 17.8), 1.00
Week 26	26.0 (13.0, 40.6), <0.001	21.9 (8.2, 37.4), <0.01
Serum PIIANP, ng/mL		
Week 4	5.8 (−0.6, 12.8), 0.24	−1.3 (−7.8, 5.7), 1.00
Week 16	2.3 (−4.1, 9.1), 1.00	7.0 (−0.4, 14.9), 0.20
Week 26	8.2 (1.3, 15.6), 0.06	2.0 (−5.1, 9.7), 1.00

Serum CTX-I, ng/mL

Week 4	10.1 (1.8, 19.1), 0.05	1.7 (−6.3, 10.4), 1.00
Week 16	11.3 (2.8, 20.5), 0.03	6.7 (−2.1, 16.4), 0.42
Week 26	9.1 (0.6, 18.4), 0.11	4.2 (−4.6, 13.7), 1.00

Urine CTX-II/creatinine, ng/mmol

Week 4	6.0 (−1.5, 14.2), 0.37	3.5 (−4.4, 12.1), 1.00
Week 16	10.6 (2.4, 19.5), 0.03	11.4 (2.4, 21.1), 0.04
Week 26	3.0 (−4.8, 11.4), 1.00	5.0 (−3.5, 14.2), 0.77

C3M=metalloproteinase-degraded type III collagen; CRPM=metalloproteinase-dependent degradation product of C-reactive protein; CTX-I=C-terminal telopeptide I; CTX-II/creatinine=C-terminal telopeptide II corrected for creatinine; HA=hyaluronic acid; PIIANP=N-propeptide of collagen IIA.

*Bonferroni-adjusted *P* value for within-group change from baseline.